Risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients

Liver Transplantation

Volumn 21, Issue 12, 2015, Pages 1511-1519

  Pereira, Marcus R ^a   Scully, Brendan F ^b   Pouch, Stephanie M ^d   Uhlemann, Anne Catrin ^a,b   Goudie, Stella ^c   Emond, Jean E ^b,c   Verna, Elizabeth C ^b,c  

^a Division of Infectious Diseases   (United States)

^b Department of Medicine ^*  (United States)

^c Department of Medicine   (United States)

^d THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZTREONAM; CARBAPENEM; CEFEPIME; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; ERTAPENEM; GENTAMICIN; LEVOFLOXACIN; MEROPENEM; MYCOPHENOLATE MOFETIL; POLYMYXIN; RIFAMPICIN; SULTAMICILLIN; TACROLIMUS; TIGECYCLINE; VANCOMYCIN;

ABDOMINAL INFECTION; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BILE LEAKAGE; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CHOLEDOCHOJEJUNOSTOMY; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KLEBSIELLA PNEUMONIAE INFECTION; LIVER CELL CARCINOMA; LIVER GRAFT; LIVER GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PENICILLIN ALLERGY; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL; URINARY TRACT INFECTION;

EID: 84977630849     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.24207     Document Type: Article

References (29)

1. Blair JE, Kusne S. Bacterial, mycobacterial, and protozoal infections after liver transplantation--part I. Liver Transpl 2005;11:1452–1459.
2. Singh N, Gayowski T, Wagener M, Yu VL. Infectious complications in liver transplant recipients on tacrolimus. Prospective analysis of 88 consecutive liver transplants. Transplantation 1994;58:774–778.
3. Wagener MM, Yu VL. Bacteremia in transplant recipients: a prospective study of demographics, etiologic agents, risk factors, and outcomes. Am J Infect Control 1992;20:239–247.
4. Bert F, Larroque B, Paugam-Burtz C, Janny S, Durand F, Dondero F, et al. Microbial epidemiology and outcome of bloodstream infections in liver transplant recipients: an analysis of 259 episodes. Liver Transpl 2010;16:393–401.
5. Singh N, Wagener MM, Obman A, Cacciarelli TV, de Vera ME, Gayowski T. Bacteremias in liver transplant recipients: shift toward gram-negative bacteria as predominant pathogens. Liver Transpl 2004;10:844–849.
6. Shi SH, Kong HS, Xu J, Zhang WJ, Jia CK, Wang WL, et al. Multidrug resistant gram-negative bacilli as predominant bacteremic pathogens in liver transplant recipients. Transpl Infect Dis 2009;11:405–412.
7. Linares L, García-Goez JF, Cervera C, Almela M, Sanclemente G, Cofán F, et al. Early bacteremia after solid organ transplantation. Transplant Proc 2009;41:2262–2264.
8. Bodro M, Sabé N, Tubau F, Lladó L, Baliellas C, Roca J, et al. Risk factors and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in solid-organ transplant recipients. Transplantation 2013;96:843–849.
9. Bradford PA, Bratu S, Urban C, Visalli M, Mariano N, Landman D, et al. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City. Clin Infect Dis 2004;39:55–60.
10. Bratu S, Mooty M, Nichani S, Landman D, Gullans C, Pettinato B, et al. Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection. Antimicrob Agents Chemother 2005;49:3018–3020.
11. Satlin MJ, Jenkins SG, Walsh TJ. The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies. Clin Infect Dis 2014;58:1274–1283.
12. Bergamasco MD, Barroso Barbosa M, de Oliveira Garcia D, Cipullo R, Moreira JC, Baia C, et al. Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae in solid organ transplantation. Transpl Infect Dis 2012;14:198–205.
13. Huprikar S. Update in infectious diseases in liver transplant recipients. Clin Liver Dis 2007;11:337–354.
14. Kalpoe JS, Sonnenberg E, Factor SH, del Rio Martin J, Schiano T, Patel G, Huprikar S. Mortality associated with carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients. Liver Transpl 2012;18:468–474.
15. Linares L, Cervera C, Hoyo I, Sanclemente G, Marco F, Cofán F, et al. Klebsiella pneumoniae infection in solid organ transplant recipients: epidemiology and antibiotic resistance. Transplant Proc 2010;42:2941–2943.
16. Mouloudi E, Massa E, Piperidou M, Papadopoulos S, Iosifidis E, Roilides I, et al. Tigecycline for treatment of carbapenem-resistant Klebsiella pneumoniae infections after liver transplantation in the intensive care unit: a 3-year study. Transplant Proc 2014;46:3219–3221.
17. Lübbert C, Becker-Rux D, Rodloff AC, Laudi S, Busch T, Bartels M, Kaisers UX. Colonization of liver transplant recipients with KPC-producing Klebsiella pneumoniae is associated with high infection rates and excess mortality: a case-control analysis. Infection 2014;42:309–316.
18. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36:309–332.
19. Patel G, Huprikar S. Infectious complications after orthotopic liver transplantation. Semin Respir Crit Care Med 2012;33:111–124.
20. Said A, Safdar N, Lucey MR, Knechtle SJ, D'Alessandro A, Musat A, et al. Infected bilomas in liver transplant recipients, incidence, risk factors and implications for prevention. Am J Transplant 2004;4:574–582.
21. Pandanaboyana S, Bell R, Bartlett AJ, McCall J, Hidalgo E. Meta-analysis of Duct-to-duct versus Roux-en-Y biliary reconstruction following liver transplantation for primary sclerosing cholangitis. Transpl Int 2015;28:485–491.
22. Pungpapong S, Alvarez S, Hellinger WC, Kramer DJ, Willingham DL, Mendez JC, et al. Peritonitis after liver transplantation: Incidence, risk factors, microbiology profiles, and outcome. Liver Transpl 2006;12:1244–1252.
23. Seehofer D, Eurich D, Veltzke-Schlieker W, Neuhaus P. Biliary complications after liver transplantation: old problems and new challenges. Am J Transplant 2013;13:253–265.
24. Verna EC, De Martin E, Burra P, Neri D, Gaglio PJ, Emond JC, Brown RS Jr, et al. The impact of hepatitis C and biliary complications on patient and graft survival following liver transplantation. Am J Transplant 2009;9:1398–1405.
25. Li C, Wen TF, Mi K, Wang C, Yan LN, Li B. Analysis of infections in the first 3-month after living donor liver transplantation. World J Gastroenterol 2012;18:1975–1980.
26. Nafady-Hego H, Elgendy H, Moghazy WE, Fukuda K, Uemoto S. Pattern of bacterial and fungal infections in the first 3 months after pediatric living donor liver transplantation: an 11-year single-center experience. Liver Transpl 2011;17:976–984.
27. Saidel-Odes L, Polachek H, Peled N, Riesenberg K, Schlaeffer F, Trabelsi Y, et al. A randomized, double-blind, placebo-controlled trial of selective digestive decontamination using oral gentamicin and oral polymyxin E for eradication of carbapenem-resistant Klebsiella pneumoniae carriage. Infect Control Hosp Epidemiol 2012;33:14–19.
28. Lübbert C, Faucheux S, Becker-Rux D, Laudi S, Dürrbeck A, Busch T, et al. Rapid emergence of secondary resistance to gentamicin and colistin following selective digestive decontamination in patients with KPC-2-producing Klebsiella pneumoniae: a single-centre experience. Int J Antimicrob Agents 2013;42:565–570.
29. Abboud CS, Bergamasco MD, Sousa EE, Zandonadi Ede C, Cortez D. Successful use of gentamycin as an antibiotic prophylaxis regimen to reduce the rate of healthcare-associated infections after renal transplantation. Braz J Infect Dis 2013;17:254–255.